Last 46 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -8.28 | — | — | — | — | — | — | — | — | — | — | 10.58 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 5460.07 | — | — | — | — | — | 45.11 | 21.45 | 1.02 | 2.31 | 5.00 | 1.23 | 1.33 |
| — | — | — | — | — | — | +801.9% | +1643.3% | -23.2% | +575.8% | +268.1% | -38.3% | -53.0% | |
| P/B Ratio | 8.61 | 3.52 | 1.51 | 2.16 | 1.60 | 0.61 | 0.42 | — | — | 10.58 | 6.61 | 4.79 | — |
| — | +480.6% | +263.1% | — | — | -94.3% | -93.7% | — | — | +72.4% | — | -58.2% | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 9.38 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 7.25 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | 7.33 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | — | — | — | — | 100.0% | -508.3% | 93.5% | -12.7% | 100.0% | 100.0% | 100.0% |
| — | — | — | — | — | — | 0.0% | -608.3% | -6.5% | -112.7% | +168.8% | 0.0% | +161.3% | |
| Operating Margin | -13811.9% | — | — | — | — | — | -31782.8% | -877.9% | -34.5% | -48.5% | -132.6% | 10.7% | -129.8% |
| — | — | — | — | — | — | -23873.7% | -8341.4% | +73.4% | -232.4% | +37.2% | +104.1% | +44.1% | |
| Net Margin | -13319.8% | — | — | — | — | — | -30201.7% | -1061.3% | -31.9% | -98.8% | -267.7% | 11.5% | -130.9% |
| — | — | — | — | — | — | -11183.5% | -9295.5% | +75.6% | -368.8% | -26.8% | +104.5% | +43.7% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -219.0% | -18.0% | -8.0% | -15.4% | -37.5% | -13.0% | -161.2% | — | — | -77.7% | -64.5% | 48.6% | — |
| — | -39.0% | +95.0% | — | — | +83.3% | -150.0% | — | — | -102.9% | — | +135.3% | — | |
| ROA | -120.5% | -15.8% | -7.1% | -11.6% | -27.7% | -9.5% | -80.7% | -17.2% | -8.6% | -13.9% | -18.2% | 4.7% | -23.4% |
| — | -66.0% | +91.2% | +33.0% | -222.6% | +31.3% | -343.4% | -469.8% | +63.2% | -149.2% | +34.2% | +116.7% | +11.9% | |
| ROIC | — | -107.5% | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 30.7% YoY to 4.62x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.00 | 0.00 | 0.02 | 0.02 | 0.03 | 0.03 | — | — | 0.54 | 0.29 | 0.04 | — |
| — | -86.2% | -85.8% | — | — | -93.7% | -88.9% | — | — | +203.2% | — | -95.0% | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 0.36 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.25 | 4.62 | 16.45 | 3.87 | 4.25 | 3.54 | 4.25 | 0.72 | 0.90 | 1.62 | 1.98 | 2.23 | 1.09 |
| — | +30.7% | +286.9% | +440.5% | +371.1% | +118.3% | +114.7% | -67.9% | -17.1% | -16.2% | +70.5% | +37.6% | -48.3% | |
| Quick Ratio | 4.25 | 4.62 | 16.45 | 3.87 | 4.25 | 3.54 | 4.25 | 0.60 | 0.81 | 1.55 | 1.92 | 2.23 | 1.09 |
| — | +30.7% | +286.9% | +539.8% | +423.6% | +128.0% | +121.6% | -72.9% | -25.4% | -19.8% | +65.1% | +37.6% | -48.3% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCidara Therapeutics, Inc.'s current P/E is -8.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Cidara Therapeutics, Inc.'s current operating margin is -13811.9%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Cidara Therapeutics, Inc.'s business trajectory between earnings reports.